1 recruiting, 1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Brian Henick, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brodalumab in the Treatment of Immune-Related Adverse Events Brodalumab, CT scan - Breast Cancer, Esophageal Cancer | Phase 1 | Recruiting | Brian Henick, MD | 11 | 2025-03-11 | 2026-05-13 |
| Liver Directed RT + Chemo-immunotherapy for ES-SCLC Carboplatin, Etoposide, Atezolizumab - Small-cell Lung Cancer | Phase 2 | Terminated | Brian Henick, MD | 2 | 2021-09-20 | 2024-12-30 |
Brain Neoplasms (1) · Breast Neoplasms (1) · Colonic Neoplasms (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Kidney Neoplasms (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Mouth Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Rectal Neoplasms (1) · Skin Neoplasms (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1)
Carboplatin (1) · Etoposide (1) · Radiosurgery (1) · atezolizumab (1) · brodalumab (1)
United States (2)